Savaysa (Edoxaban) is a blood thinner that may lead to uncontrollable bleeding injuries. Manufactured and distributed by Daiichi Sankyo, Savaysa is prescribed to help reduce the risk of stroke due to atrial fibrillation. Also known also as Edoxaban, it is a Factor Xa inhibitor, a new class of new anticoagulants, which includes Xarelto and Eliquis. We have already filed lawsuits against the manufacturers and distributors Xarelto and Eliquis, and are continuing to investigate cases involving bleeds from these drugs.
We are currently investigating claims on behalf of injured users of Savaysa. Our firm will handle your case from start to finish. If you or someone you know has suffered from a bleeding injury due to taking this drug the lawyers at Rheingold Giuffra Ruffo & Plotkin LLP are here to help you explore your legal options. We have experience in litigating cases against Daiichi Sankyo, and are currently involved in a number of lawsuits against the company for its hypertension drug, Benicar.
Serving Clients Across the Nation
Savaysa and Uncontrolled Bleeding
At Rheingold Giuffra Ruffo & Plotkin LLP, we have been helping people from New York and across the nation with their most critical legal problems for over 30 years. We handle a wide range of drug liability and defective medical device claims, including those involving Savaysa.
With other drugs, such as warfarin, bleeding was easy to stem by using vitamin K and plasma. However, Savaysa belongs to a group of new anticoagulants that do not have reversal agents to stop their blood-thinning effects in case of a bleeding event. This fact, that there is no established way to reverse Savaysa anticoagulant effect can lead to life-threatening consequences. Other injuries from Savaysa include rectal bleeding, intestinal bleeding and brain hemorrhaging.
Our attorneys will work with you personally to determine the extent of the monetary damage this drug has caused you, and what legal remedies are at your disposal. Our goal is to help you obtain monetary compensation for the financial hardships you face.
Black Box Warning
For a number of years before its approval in the U.S., Savaysa had been used across the world under the name Lixiana. When granted federal approval, the FDA required a black box warning be added to the Savaysa label warning against use by patients with high functioning kidneys. Patients with high functioning kidneys "have an increased risk of stroke compared to similar patients given warfarin. Savaysa should not be used in nonvalvular atrial fibrillation patients with a higher creatinine clearance."